ACS CAN: Cancer patients should be exempt from possible Medicaid work requirements

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The Centers for Medicare and Medicaid Services issued guidance allowing states to require “able-bodied” adults to work, participate in job training or volunteer in order to receive Medicaid health benefits.

As part of the guidance, CMS exempts children, pregnant women, the disabled and those who are deemed, “medically frail,” however the guidance does not clearly define who would be considered medically frail.

A statement from Chris Hansen, president of the American Cancer Society Cancer Action Network follows:

“Today’s guidance could mean a significant change to one of America’s most essential safety-net programs. Medicaid serves as a vital lifeline that provides health care coverage to more than 2.3 million low-income Americans with a history of cancer.

“Many cancer patients in active treatment are often unable to work or require significant accommodations to their work schedules due to that treatment. It is unclear from the guidance what standards states would use to define “medically frail.”

Research suggests between 40 and 85 percent of cancer patients stop working while receiving cancer treatment, with absences ranging from 45 days to six months. Additionally, evidence shows that patients who have recently completed treatment may need additional time to recover and transition back into the workplace.

“We strongly urge CMS to require states exempt people with serious, complex medical conditions, particularly cancer patients and recent survivors from any work requirements…”

YOU MAY BE INTERESTED IN

Physician-scientists by day, a funk-loving musical troupe by night. You may have seen The CheckPoints—a 13 member cover band with a three-piece brass section and Jim Allison on harmonica—movin’, groovin’, and gettin’ down as a mainstay closing act at ASCO, AACR, or the Society for Immunotherapy of Cancer annual meetings. 
At the 2026 Annual Meeting of the American Society of Clinical Oncology in Chicago, results from the phase III HARMONi-6 trial were presented at the plenary session and published simultaneously in The Lancet. The HARMONi-6 trial tested a novel bispecific antibody that engages PD-1 and VEGF (ivonescimab), given with platinum-doublet chemotherapy to patients with previously untreated advanced squamous non-small cell lung cancer. 
In 2026, more than 900 million people are estimated to be regularly using generative artificial intelligence—computer systems capable of creating human-like text, images, audio, video, and other original content. AI is becoming integrated into nearly every aspect of daily life. Health care is no exception. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login